New device provides one-step vessel and tissue sealing
Improves efficiency during laparoscopic and open procedures
BOULDER, Colo.--(BUSINESS WIRE)--Jan. 22, 2014--
Expanding its industry-leading vessel and tissue sealing portfolio, Covidien
(NYSE:COV) received U.S. Food and Drug Administration (FDA) 510(k)
clearance for the LigaSure™ Maryland jaw open/laparoscopic
sealer/divider. In addition, Covidien completed all European
requirements to CE Mark the product. The company expects to launch the
new vessel sealer and divider in the United States and the European
Union during the current quarter.
The U.S. Food and Drug Administration cleared Covidien's LigaSure Maryland jaw vessel sealer and divider in three lengths for use in open and laparoscopic surgery.
(Photo: Business Wire)
Designed to improve efficiency during laparoscopic and open surgery, the
LigaSure Maryland jaw device combines LigaSure’s energy-based vessel
sealing technology with the functionality of three common surgical
tools: a Maryland dissector, which is a blunt surgical tool with a
curved jaw used to separate, grasp and manipulate tissue; an atraumatic
tissue grasper and cold surgical scissors. The design of the new
LigaSure Maryland jaw device allows surgeons to grasp, seal and cut
tissue with minimal steps and reduced instrument exchanges.
“For more than 15 years, surgeons have trusted LigaSure technology for
its ability to reduce blood loss,1,2 shorten procedure time1,2
and shorten the length of hospital stay1 compared to
sutures,” said Chris Barry, President, Advanced Surgical, Covidien. “The
LigaSure Maryland jaw offers surgeons an efficient, versatile and
multifunctional option for one-step sealing and further demonstrates
Covidien’s commitment to expand energy device options with solutions
targeted at specific procedures and surgeon use needs.”
Setting the industry standard, LigaSure technology has been used in more
than 8 million vessel sealing procedures worldwide.
LigaSure vessel sealing technology is powered by the ForceTriad™ energy
platform, controlled by TissueFectTM sensing technology,
which monitors changes in tissue 3,333 times per second and adjusts
energy output accordingly to deliver the appropriate amount of energy
for the desired tissue effect. LigaSure vessel sealing uses the body’s
own collagen and elastin to create a permanent fusion zone. Covidien’s
proprietary technology can fuse vessels up to and including 7 mm,
lymphatics, tissue bundles and pulmonary vasculature.
The LigaSure Maryland jaw device comes in three lengths. Covidien plans
to roll out the 37 cm version to select customers early in 2014 and
launch the shorter 23 cm and longer 44 cm options later this year.
Covidien designed the LigaSure Maryland jaw device for use in minimally
invasive procedures including urologic, vascular, thoracic and
thoracoscopic, and gynecologic procedures where ligation and division of
the vessels is performed.
For more information on LigaSure products, visit: http://surgical.covidien.com/products/vessel-sealing#technology
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers
value through clinical leadership and excellence. Covidien develops,
manufactures and sells a diverse range of industry-leading medical
device and supply products. With 2013 revenue of $10.2 billion, Covidien
has more than 38,000 employees worldwide in more than 70 countries, and
its products are sold in over 150 countries. Please visit www.covidien.com
to learn more about our business.
1 Ding Z, Wable G, Rane A. Use of Ligasure bipolar diathermy
system in vaginal hysterectomy. J Obstet Gynaecol. 2005;25(1): 49-51.
2 Levy B, Emery L. Randomized trial of suture versus
electrosurgical bipolar vessel sealing in vaginal hysterectomy. Obstet
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140122005390/en/
Source: Covidien plc
John Jordan, 508-452-4891
Lannum, CFA, 508-452-4343
Vice President, Investor Relations
Vice President, Communications
Senior Director, Investor Relations